APGE Apogee Therapeutics, Inc.

3

Healthcare [ 6/11 ] | Biotechnology [ 90/148 ]

US | NASDAQ | Stock

Price
$19.98
Decreased by -4.26%
Dollar Volume (20D)
10.71 M
ADR%
6.76
Earnings Report Date (estimate)
Nov 27, 23 (-0.38)
Market Cap.
1.01 B
Shares Float
24.81 M
Shares Outstanding
50.67 M
Beta
0.00
Price / Earnings
N/A
BPR
0.04
20D Range
19.79 25.41
50D Range
19.79 25.54
200D Range
19.79 25.54
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 28, 23 3.78 1.70
Increased by +122.35%
Jul 17, 23 -3.78 1.70
Decreased by -322.35%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.